Corporate Announcement
- Sakar submitted 20 dossiers of oncology product registration across regions
- Sakar enters into agreement with 7-partners
- Sakar s oncology (anti-cancer) unit receives EU GMP approval
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the
quarter ended on March 31, 2024
- Investor Conference
- Sakar Interaction with Investor 24th Feb. 2023
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on September 30, 2023
- Amendment to MOA AND AOA
- WHO GMP approval received for Oncology Injection (small volume parenteral & lyophilized) unit
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on March 31, 2023
- Meeting with strategic global team of Ferring Pharmaceutical
- Sakar_Interaction_with_Investor_14th November 2022
- Updates_on_API_progressed_ in_oncology_segment
- Sakar_Interaction_with_Investor_2nd November 2022
- Sakar_Interaction_with_Investor_12th October 2022
- WHO_GMP_Approval
- Sakar Interaction with Investor 8th October 2022
- Sakar Healthcare enters into an Agreement with Zydus Life Sciences (Cadila Healthcare) to manufacture Oncology
- Sakar Interaction with Investor 29th Sept. and 1st October 2022
- Auditors Appointment
- Sakar Interaction with Investor Analyst 21st Sept. 2022
- Sakar Interaction with Investor Analyst 9th Sept. 2022
- Sakar Interaction with Investor Analyst 2nd and 3rd Sept. 2022
- Broker Conference on 29th June, 2022
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on December 31, 2021
- Change in Chief financial officer
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on September 30, 2021
- Re-appointment of directors in 17th AGM
- SAKAR Healthcare - Inauguration of Research Laboratories (R&D, F&D, ADL)
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on June 30, 2021
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on March 31, 2021
- FPI Investment in Sakar Healthcare
- Stakeholder Communication
- Amendment in Memorandum of Association
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 for Re-appointment of Statutory Auditor
- Business Expansion Oncology
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015 for the quarter ended on March 31,2019
- Updates - Emerging Bigger
- Non-applicability-of-large-Entities
- Announcement DSIR
- Intimation Letter - submission advertisement publication dated 18th January 2019
- Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015 , dated 17th January 2019
- Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015 for submission of advertisement publication
- Sakar Healthcare Investor Presentation
- Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015 , dated 29th November 2018
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015
- Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015
- Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015 for change in the Company Secretary
- Corrigendum to the Notice of the EGM to be held on 20th March 2018
- Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015
- Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015, 19th January 2018
- Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015, 9th june 2017
- Statement of Deviation or Variation under regulation 32 of SEBI(LODR) Regulations, 2015
- Intimation Letter under regulation 30 of SEBI (LODR) Regulations, 2015
